中华放射肿瘤学杂志
Saturday, Jan. 18, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2022, Vol. 31 Issue (1): 90-96    DOI: 10.3760/cma.j.cn113030-20200601-00288
Review Articles Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Postoperative radiotherapy for non-small cell lung cancer treated with neoadjuvant chemotherapy followed by surgery
Bao Yongxing1, Hui Zhouguang2
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Neoadjuvant chemotherapy followed by surgery (NCS) is a common therapy pattern of non-small cell lung cancer (NSCLC). However, patients treated with NCS still suffer from relatively high locoregional recurrence. Postoperative radiotherapy (PORT) plays an important role in improving locoregional control, whereas its effect on survival remains controversial. Some studies propose that PORT yields no survival benefits for stage Ⅱ-ⅢA(N2) patients treated with NCS, whereas other researches indicate that PORT can bring survival benefits for high-risk patients. The indications of PORT include R1/R2 resection and ypN2. PORT is recommended with three-dimensional conformal therapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) within the dose range of 50-54Gy (R0 resection). The target volume is inconclusive and the irradiation range of mediastinum involving with the metastatic lymph node regions is recommended in many studies.The adverse effects of PORT are acceptable in most studies.Nevertheless, the evidence level of relevant studies is relatively low. These results remain to be clarified by prospective randomized clinical trials.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Bao Yongxing
Hui Zhouguang
Key wordsCarcinoma, non-small cell lung/postoperative radiotherapy      Carcinoma, non-small cell lung/neoadjuvant chemotherapy      Research progress     
Received: 01 June 2020     
Fund:National Key R&D Program of China (2017YFC1311000); Clinical Application Project of Beijing Municipal Commission of Science and Technology (Z171100001017114); CAMS Key lab of translational research on lung cancer (2018PT31035); Ministry of Education Innovation Team development project (IRT-17R10)
Corresponding Authors: Hui Zhouguang, Email:drhuizg@163.com   
Cite this article:   
Bao Yongxing,Hui Zhouguang. Postoperative radiotherapy for non-small cell lung cancer treated with neoadjuvant chemotherapy followed by surgery[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 90-96.
Bao Yongxing,Hui Zhouguang. Postoperative radiotherapy for non-small cell lung cancer treated with neoadjuvant chemotherapy followed by surgery[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 90-96.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200601-00288     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I1/90
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn